

## Atypical presentations of celiac disease

Can Celiloğlu<sup>1</sup>, Hamza Karabiber<sup>2</sup>, Mukadder Ayşe Selimoğlu<sup>2</sup>

<sup>1</sup>Department of Pediatrics, Malatya State Hospital and <sup>2</sup>Department of Pediatric Gastroenterology, Hepatology and Nutrition, İnönü University Faculty of Medicine, Malatya, Turkey

**SUMMARY:** Celiloğlu C, Karabiber H, Selimoğlu MA. Atypical presentations of celiac disease. *Turk J Pediatr* 2011; 53: 241-249.

Celiac disease (CD) has a wide variety of clinical presentations; together with the “classical form”, in which the intestinal symptomatology is prevalent, there are “atypical forms” with predominating extra-intestinal clinical features, and the “silent form”, with no clinical symptom.

The “atypical forms” of the disease are characterized by few or no gastrointestinal symptoms, and predominating extra-intestinal features such as neurologic, dermatologic, hematologic, endocrinologic, reproductive, renal, psychiatric, skeletal, and liver involvement(s). Silent presentation of CD may be identified through screening of high-risk groups.

Today, it is well known that CD might account for several chronic health issues, so it is essential for healthcare professionals to have a high level of suspicion for the atypical presentations of CD.

*Key words:* celiac disease, atypical.

Celiac disease (CD) is a highly prevalent autoimmune disorder that is triggered by the ingestion of wheat gluten and related proteins of rye and barley in genetically susceptible individuals<sup>1</sup>. The pathogenesis is based on the sensitivity against gluten that results in inflammation and atrophy of the mucosa of the small intestine. Genetic, environmental and immunological factors may play a role in the pathogenesis<sup>2</sup>. CD is known to be an important causative factor for both gastrointestinal (GI) and systemic symptoms and signs, and is considered as a multisystemic disorder<sup>3</sup>.

### Clinical Presentations

Celiac disease (CD) has a wide variety of clinical presentations; together with the “classical form”, in which the intestinal symptomatology is prevalent, there are “atypical forms” with predominating extra-intestinal clinical features and the “silent form” with no clinical symptom. The typical clinical manifestations of the disease are encountered during the early periods of life, and the clinical spectrum of the disease broadens during the following years<sup>2</sup>.

The notion about CD is evolving; it is now recognized that children with CD, in whom

the diagnosis is somehow delayed, the disease may present itself later with either typical or atypical manifestations. The classical form presenting with mainly diarrhea and malabsorption syndrome, which used to be the leading presentation among children, is reported to be decreasing<sup>4,5</sup>. The decreased rate of CD with typical symptoms is partly due to the increased awareness of the disease, introduction of several serological markers and the increased rate of the early diagnosis<sup>6</sup>.

The Canadian Celiac Association’s survey, conducted in 1989-91, which included 1294 respondents with biopsy-confirmed CD, reported that over 60% of the respondents, including both children and adults, had to consult three or more physicians before the diagnosis was made<sup>7</sup>. Makharia et al.<sup>8</sup> reported that almost half of the adult patients with CD presenting with atypical manifestations consulted physicians other than gastroenterologists.

### “Atypical” Clinical Forms

The ‘atypical’ forms of the disease are characterized by few or no GI symptoms, and predominating extra-intestinal features such as refractory iron deficiency anemia, osteoporosis,

short stature, pubertal delay, infertility, and recurrent spontaneous abortions (Table I)<sup>9,10</sup>.

### Nervous System Involvement

After the first report of Cooke and Smith<sup>11</sup> in 1966, numerous papers have been published reporting the association of CD and neurological symptoms. Neurological symptoms may precede or follow the diagnosis of CD, representing sometimes the only clinical manifestations.

Peripheral neuropathy and cerebellar ataxia are the most common neurological deficits in CD<sup>11-16</sup>. Other neurological symptoms include occipital calcifications<sup>17</sup>, seizures<sup>18</sup>, headache<sup>19</sup>, and myopathy<sup>20</sup>.

Luostarinen et al.<sup>21</sup> conducted a study on 26 patients with CD and found that 31% had abnormalities in neurophysiologic studies, compared with only 4% of controls with reflux disease.

The frequency of unknown CD in patients with neuropsychological symptoms is about 16%, and in a recent study, approximately 7% of new CD cases were diagnosed in the presence of neuropsychological disorders<sup>22</sup>.

The pathogenesis of neurological damage is poorly understood, and the response to a gluten-free diet (GFD) is still controversial<sup>23</sup>. Humoral immune mechanisms have been proposed in the pathogenesis of both ataxia and peripheral neuropathy. Antibodies to gliadin that cross-react with Purkinje cells have been inconsistently reported in the sera of celiac patients with ataxia<sup>24,25</sup>, antibody reactivity to neural antigens was identified<sup>26</sup>, and IgG antibodies to gangliosides have been found in adult CD patients with neuropathy and other neurological manifestations<sup>12,27,28</sup>. The possible role of auto reactivity to gangliosides in CD is unclear<sup>29</sup>. A recent study in a cohort of celiac children did not find a correlation between antibodies to gangliosides and neurological manifestations or GFD<sup>29</sup>. Nutritional factors have also been suspected in the etiology of the neurological deficits, but clear evidence is lacking. Today, the link between CD and neurological disorders is partly attributed to the genetic background, most importantly the HLA region on chromosome 6 and other markers<sup>3</sup>. The link between the most frequent neurological deficits described and gluten

sensitivity remains to be identified through further molecular/immunological studies.

### Musculoskeletal System Involvement

Both osteomalacia and osteoporosis have been reported to be associated with CD (30,31). Numerous factors including secondary hyperparathyroidism due to vitamin D deficiency as well as systemic inflammation seen with CD (32-34) have been postulated to affect bone mineral density (BMD) in CD. Vitamin D activity is also impaired, with reduced vitamin D-dependent transporter protein seen in active CD<sup>35-37</sup>. Indeed, decreased BMD has been reported even in patients with clinically silent CD<sup>4</sup>. CD has also been linked to impaired zinc absorption, leading to a reduction of insulin-like growth factor (IGF)-1, which has been correlated with decreased BMD<sup>34,38-41</sup> and to amenorrhea or male hypogonadism, which could also contribute to decreased bone mass<sup>42,43</sup>. The reduced BMD, associated with an increased risk of fracture, improves after a GFD, but reduced BMD might not attain the normal levels<sup>44</sup>.

Neuromuscular disorders may be the presenting feature of CD. Muscle involvement is reported as a rare complication of CD. Vitamin E deficiency was reported as an etiologic factor in the pathogenesis of the myopathies associated with CD<sup>45</sup>.

Arthritis is reported as an infrequent presentation of CD<sup>46</sup>.

### Liver Involvement

In 1977, Pollock<sup>47</sup> first reported a possible association between CD and liver dysfunction. During the following decades, several hepatic disorders have been described in association with CD.

Today, it is well known that isolated hypertransaminasemia with nonspecific histological changes in a liver biopsy is the most common hepatic presentation of CD. In one study, a total of 114 consecutive pediatric CD patients were included, and hypertransaminasemia was found in 32% of them; in 5 patients, it was the only manifestation of CD (4.3%). Younger age was reported to be significantly associated with hypertransaminasemia, and the aminotran-

**Table I.** Summary of Disorders Associated with CD and/or Atypical Manifestations of CD

<p><b>NERVOUS SYSTEM</b>                      Peripheral neuropathy                      Cerebellar ataxia                      Occipital calcifications                      Seizures                      Headache                      Myopathy                      Neuropsychological disorders</p> <p><b>LIVER DISORDERS</b>                      Isolated hypertransaminasemia                      Autoimmune hepatitis                      Primary biliary cirrhosis                      Primary sclerosing cholangitis                      Hemochromatosis                      Massive hepatic steatosis                      Cirrhosis</p> <p><b>HEMATOLOGICAL SYSTEM</b>                      Iron deficiency anemia                      Macrocytic anemia                      Blood-count abnormalities (leukopenia, thrombocytopenia)                      Splenic hypofunction                      Thrombocytosis                      Venous thrombosis                      Prolongation of coagulation assays                      Selective IgA deficiency</p> <p><b>ENDOCRINOLOGIC AND AUTOIMMUNE DISORDERS</b>                      Insulin-dependent diabetes mellitus                      Autoimmune thyroid disease                      Sjögren's syndrome                      Addison's disease                      Autoimmune liver disease                      Cardiomyopathy</p> <p><b>ONCOLOGICAL DISORDERS</b>                      Non-Hodgkin lymphoma                      Small bowel adenocarcinoma                      Esophageal and oropharyngeal squamous carcinomas</p> <p><b>RENAL SYSTEM</b>                      IgA nephropathy                      Chronic glomerulonephritis                      Renal failure</p> <p><b>PULMONARY SYSTEM</b>                      Idiopathic pulmonary hemosiderosis</p>	<p><b>MUSCULOSKELETAL SYSTEM</b>                      Osteomalacia                      Osteoporosis                      Arthritis                      Myopathy</p> <p><b>DERMATOLOGIC SYSTEM</b>                      Dermatitis herpetiformis                      Xerosis                      Alopecia areata                      Dermatomyositis                      Cutaneous vasculitis                      Urticaria                      Atopic dermatitis                      Prurigo nodularis                      Psoriasis                      Chronic ulcerative stomatitis                      Linear IgA dermatosis                      Vitiligo                      Lupus erythematosus                      Lichen sclerosus                      Palmoplantar pustulosis                      Keratosis pilaris                      Pityriasis rubra pilaris                      Erythroderma                      Necrolytic migratory erythema                      Cutaneous amyloidosis                      Annular erythema                      Partial lipodystrophy                      Generalized acquired cutis laxa                      Ichthyosis                      Transverse leukonychia                      Erythema elevatum diutinum                      Cutaneous sarcoidotic granuloma</p> <p><b>REPRODUCTIVE SYSTEM</b>  <u>Male</u>                      Hypogonadism                      Impotence                      Immature secondary sex characteristics                      Reduced semen quality                      Altered spermatic motility                      Loss of libido                      Infertility</p> <p><b>PSYCHIATRIC</b>                      Schizophrenic symptoms                      Major depression                      Affective disorders                      Social phobia</p>	<p><u>Female</u>                      Delayed menarche                      Amenorrhea                      Recurrent abortions                      Reduced pregnancy rate                      Early menopause                      Loss of libido                      Infertility</p>
--	--	---

sferases normalized with a GFD in all 35 patients who were followed for an average period of one year<sup>48</sup>. On the other hand, hypertransaminasemia observed in CD may be partly attributed to muscle injury including rhabdomyolysis<sup>45</sup>. Two pediatric cases pointing to this possible association have been reported<sup>49</sup>.

Celiac disease (CD) can coexist with autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Primary biliary cirrhosis was clearly linked to CD with two large population-based studies<sup>50,51</sup>. Primary sclerosing cholangitis was first found to be associated with CD in 1988 in three patients with diarrhea and steatorrhea, but larger series

regarding the link between primary sclerosing cholangitis and CD are missing. Association of autoimmune hepatitis and CD has been evaluated in only a limited number of case reports and survey studies. Unfortunately, many appeared before hepatitis C testing<sup>52</sup>. The possible association between these disorders and CD was attributed to the possibly common immunologic/pathological pathways.

Celiac disease (CD) has also been associated with hemochromatosis; both are associated with the HLA-region on chromosome 6<sup>52,53-55</sup>. Butterworth et al.<sup>56</sup> observed that HFE (hemochromatosis susceptibility gene) locus mutations are common in CD patients from the United Kingdom and may be important in protecting CD patients from iron deficiency, while others suggested that the significance of these observations may be controversial<sup>57</sup>.

In addition to the immune-based damage, chronic changes in liver chemistry tests may reflect a direct effect of CD. For instance, impaired absorption and resultant malnutrition may lead to deposition of fat in the liver, which leads to reduced fat mobilization from hepatocytes. Indeed, massive hepatic steatosis has occasionally been reported in CD. Finally, but very rarely, patients may develop a specific complication of CD that involves the liver, such as a T-cell form of lymphoma<sup>52</sup>.

Mildly abnormal liver biochemistry may provide a shortcut for the early diagnosis of CD. Routine investigations for undiagnosed liver disease should include tissue transglutaminase testing. If left untreated, celiac-induced hepatitis may rarely progress to end-stage liver disease.

### Dermatologic Findings

Various visceral and skin-mucosal involvements have been described in association with CD<sup>58</sup>. Dermatitis herpetiformis (DH), alopecia areata, dermatomyositis, cutaneous vasculitis, urticaria, atopic dermatitis, prurigo nodularis, psoriasis, and chronic ulcerative stomatitis are the main dermatological associations of CD that have been reported<sup>58</sup>.

Linear IgA dermatosis, vitiligo, lupus erythematosus, lichen sclerosus, palmoplantar pustulosis, pityriasis rubra pilaris, erythroderma, necrolytic migratory erythema, cutaneous amyloidosis, annular erythema, partial

lipodystrophy, generalized acquired cutis laxa, ichthyosis, transverse leukonychia, erythema elevatum diutinum, and cutaneous sarcoidotic granuloma cases linked to CD were also reported<sup>58-61</sup>. One of the few studies conducted in Turkey describing the dermatologic findings associated with CD showed that cutaneous, mucosal, nail, and hair findings were detected in 74.5%, 27.3%, 20.0%, and 7.3% of patients, respectively. The most prevalent dermatologic diagnosis was xerosis (69.1%) followed by keratosis pilaris (32.7%). No significant relationship was detected between the cutaneous findings and the duration of the illness<sup>62</sup>.

However, the only proven association of CD with dermatological disorders is DH<sup>58</sup>. DH, an intensely pruritic vesicular rash found anywhere on the body, is one of the leading modes of clinical manifestation of CD<sup>3,63</sup>. The skin biopsy shows the characteristic lineal, granular deposits of IgA in the dermal papillae<sup>3</sup>. This condition affects about 15-25% of patients with CD<sup>3</sup>. Although dapsone controls skin lesions of DH, a GFD allows patients to discontinue the drug.

Patients with alopecia areata were found to be at high risk of CD, but sufficient evidence for this association is missing<sup>58</sup>. Recurrent aphthous ulceration is the presenting symptom of CD in 10-40% of patients with untreated CD. Other oral lesions can also occur, including the geographic atrophic glossitis due to B vitamin deficiency and the dental enamel hypoplasia related to a deficit in the dentin synthesis (64).

### Hematologic Findings

Celiac disease (CD) is a common cause of various hematological disorders, the most common of which is anemia. The proximal intestine, the absorption site of dietary iron, is damaged during the course of CD, and it is not surprising that iron deficiency anemia is prevalent among newly diagnosed cases. The anemia associated with CD may also be due to malabsorption of micronutrients such as folic acid and vitamin B12<sup>65</sup>. It is also frequently implicated in the etiology of other blood-count abnormalities, splenic hypofunction and intestinal lymphomas<sup>66</sup>.

Bottaro et al.<sup>4</sup> reported iron deficiency anemia as the most frequent extra-intestinal symptom among both pediatric and adult CD patients<sup>4</sup>. According to an Indian report, besides short stature, refractory iron deficiency anemia was found to be one of the leading modes of presentation of atypical CD<sup>67</sup>. The prevalence of CD in patients referred for GI endoscopy for investigation of iron deficiency anemia varies from 3% to 12%<sup>68,69</sup>. The iron deficiency in CD primarily results from impaired absorption of iron but there may also be occult blood loss in the GI tract<sup>70,71</sup>. Occult GI blood loss was seen in 26.7% of children with CD and appears to respond to treatment with a GFD<sup>72</sup>. More recent studies have suggested, however, that occult GI bleeding in patients with CD may be much less common<sup>73,74</sup>.

Celiac disease (CD) may also induce folate deficiency<sup>75</sup> and vitamin B12 deficiency presenting with macrocytic anemia, leukopenia and thrombocytopenia<sup>65</sup>. Copper deficiency has also been described in adults and children with CD and may result in anemia and thrombocytopenia<sup>76,77</sup>. Deficiencies of both folate and copper have been implicated as a possible etiology for the leukopenia<sup>65</sup>.

Thrombocytopenia has been reported rarely in patients with CD and may be autoimmune in nature<sup>65</sup>. Thrombocytosis in association with CD appears to be more common than thrombocytopenia, occurring in up to 60% of patients<sup>65</sup>. The exact etiology of the thrombocytosis is unknown, but it may be secondary to inflammatory mediators or, in some cases, secondary to iron deficiency anemia or functional hyposplenism. The thrombocytosis may resolve after institution of a GFD<sup>65</sup>.

Venous thrombosis has been reported in CD. Hyperhomocysteinemia is a frequent finding in CD and may be related to an increased tendency to form clots<sup>78</sup>. CD may also be associated with coagulopathy. Malabsorption of vitamin K results in a decrease in K vitamin-dependent coagulation factors and results in prolongation of coagulation assays such as the prothrombin time (PT), international normalized ratio (INR) and the activated partial thromboplastin time (aPTT)<sup>79</sup>. Nevertheless, it was found irrational to screen for CD in patients with isolated coagulation disorders<sup>80</sup>.

### Endocrinologic and Autoimmune Presentation

Autoimmune disorders arise 10 times more often in patients with CD compared to the general population<sup>81</sup>, including type 1 diabetes mellitus (DM), thyroid disease, Sjögren's syndrome, Addison's disease, autoimmune liver disease, cardiomyopathy, and neurological disorders. The association of autoimmune disorders and CD is thought to be related to a shared genetic tendency (HLA alleles) and a common immunological mechanism in addition to the presence of CD itself<sup>81</sup>.

The two most common forms of endocrinologic pathologies seen with CD are type 1 DM, and thyroid disease<sup>3</sup>. Ansaldi et al.<sup>82</sup> performed a study in Italian children and found a high incidence of autoimmune thyroid disease in 90 of 343 (26.2%) patients with CD (62 on GFD) and in 20 (10%) of the control subjects ( $p=0.001$ ). The high prevalence of CD among type 1 DM emphasizes the need for routine screening in that population<sup>83</sup>.

The high frequency of autoimmune thyroid disease found among patients with CD, even those on a GFD, may justify a thyroid status assessment at diagnosis and at follow-up evaluation of patients with CD<sup>84</sup>.

### Oncological Aspects

It is generally accepted that CD is associated with an increased risk of non-Hodgkin lymphoma, small bowel adenocarcinoma and esophageal and oropharyngeal squamous carcinomas<sup>81,85</sup>. The predominant celiac-associated lymphoma is the enteropathy-associated T-cell lymphoma, which has a poor prognosis and is rapidly fatal<sup>85</sup>.

The mechanisms responsible for the development of malignancies during the course of CD are not established<sup>3</sup>. A strict GFD is thought to be protective against the development of malignant disease<sup>86</sup>, although this might not be the case for the development of non-Hodgkin lymphoma<sup>87</sup>.

### Reproductive System Problems

Both males and females with CD may present disorders related to the reproductive system. In particular, female CD patients may present with delayed menarche, amenorrhea, infertility

with recurrent abortions, early menopause, and a reduced pregnancy rate<sup>43,88</sup>. In male CD patients, hypogonadism, impotence, immature secondary sex characteristics, reduced semen quality, altered spermatic motility, and infertility have been described<sup>43,88</sup>.

The pathogenesis of reproductive disorders associated with CD is not clear, and various hypotheses have been suggested<sup>89</sup>. The first is that gluten acts as an auto-antigen and produces immunogenic response toward organs and hormones required for pubertal development. This hypothesis can explain the pubertal delay in girls; however, it cannot explain the androgen resistance detected in boys. Another hypothesis is malabsorption of micronutrients required for sex hormone-binding globulins, metabolism of receptor proteins and increased cytokine (particularly interleukin 6) production. As iron, folic acid and B vitamins are critical for development in children and adolescents, dietary deficiencies or absorption disorders might result in pubertal delay<sup>88,90</sup>.

Celiac disease (CD) is also associated with reduced frequency of sexual intercourse<sup>91</sup>. Hyperprolactinemia is seen in 25% of celiac patients, which causes impotence and loss of libido. Gluten withdrawal and correction of deficient dietary elements can lead to a return of fertility in both men and women<sup>43</sup>.

Patients with CD were also reported to have premature babies or babies with low birth weight with increased perinatal mortality and a shorter duration of breast feeding<sup>92-94</sup>. According to our unpublished data, the CD prevalence was found to be 1.3% and 1.9%, respectively, in the mothers and fathers of babies either born prematurely or with low birth weight. The prevalence of CD in those with healthy babies was 0.8%.

### Nephrologic Findings

Various reports contributing to the association of renal diseases and CD have been conducted. Collin et al.<sup>95</sup> reported that patients with IgA nephropathy are at increased risk for CD. Fornasieri et al.<sup>96</sup> found evidence of CD in 2/121 patients with IgA nephropathy. Recently, Ludvigsson et al.<sup>97</sup> reported that CD is associated with an increased risk of chronic glomerulonephritis and renal failure.

Immune characteristics associated with CD were suspected to increase the risk of chronic renal disease; individuals with CD were also reported to be at a moderately increased risk of any form of glomerulonephritis<sup>97</sup>.

### Psychiatric Findings

Patients with CD may present with schizophrenic symptoms, major depression<sup>75,98</sup>, as well as affective disorders such as the state-reactive form of anxiety and current depression<sup>64</sup>. A significantly higher prevalence of social phobia in CD patients compared with healthy subjects was also reported<sup>99</sup>.

Several possible factors and mechanisms have been hypothesized in order to explain the high prevalence of affective disorders in CD patients. A reduced neuronal production of monoaminergics represents one of the mechanisms currently implicated in the pathogenesis of behavioral disorders. Hallert et al.<sup>100</sup> showed a significant reduction of serotonin metabolites in cerebrospinal fluid of CD patients.

### Pulmonary Involvement

Idiopathic pulmonary hemosiderosis (IPH) is a rare disease of unknown autoimmune etiology mainly affecting children and adolescents<sup>101</sup>. The association of IPH and CD is well known and is attributed to the common pathogenetic/immunological mechanisms. For IPH patients with CD, GFD without any steroids or immunosuppressants was reported to be very effective. Patients suffering from IPH should be screened for CD even in the absence of the GI symptoms.

### CONCLUSION

Celiac disease (CD) may present with a wide spectrum of symptoms and signs (Table I). It is a frequent disorder, and since many patients with CD have the silent/atypical form, physicians should be aware of those atypical manifestations and high-risk populations in order to avoid underdiagnosis of the disease.

### REFERENCES

1. Selimoğlu MA, Karabiber H. Celiac disease: prevention and treatment. *J Clin Gastroenterol* 2010; 44: 4-8.
2. Demir H, Yüce A, Koçak N, Özen H, Gürakan F. Celiac disease in Turkish children: presentation of 104 cases. *Pediatr Int* 2000; 42: 483-487.

3. Rodrigo L. Celiac disease. *World J Gastroenterol* 2006; 12: 6585-6593.
4. Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. *Am J Gastroenterol* 1999; 94: 691-696.
5. Ludvigsson JF, Ansved P, Fälth-Magnusson K, et al. Symptoms and signs have changed in Swedish children with coeliac disease. *J Pediatr Gastroenterol Nutr* 2004; 38: 181-186.
6. Poddar U, Thapa BR, Singh K. Clinical features of celiac disease in Indian children: are they different from the West? *J Pediatr Gastroenterol Nutr* 2006; 43: 313-317.
7. Champion MC, Davidson AG, Campbell JA, on behalf of the Canadian Celiac Association. The Canadian Celiac Association National Survey of patients with celiac disease. *Clin Invest Med* 1991; 14: A923.
8. Makharia GK, Baba CS, Khadgawat R, et al. Celiac disease: variations of presentations in adults. *Indian J Gastroenterol* 2007; 26: 162-166.
9. Gasbarrini G, Ciccocioppo R, De Vitis I, Corazza GR; Club del Tenue Study Group: Celiac disease in the elderly: a multicenter Italian study. *Gerontology* 2001; 47: 306-310.
10. Corazza GR, Gasbarrini G. Coeliac disease in adults. *Baillieres Clin Gastroenterol* 1995; 9: 329-350.
11. Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. *Brain* 1966; 89: 683-722.
12. Chin RL, Latov N. Peripheral neuropathy and celiac disease. *Curr Treat Options Neurol* 2005; 7: 43-48.
13. Hadjivassiliou M, Grunewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. *J Neurol Neurosurg Psychiatry* 2002; 72: 560-563.
14. Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ, Milford-Ward A. Does cryptic gluten sensitivity play a part in neurological illness? *Lancet* 1996; 347: 369-371.
15. Luostarinen LK, Collin PO, Peräaho MJ, Mäki MJ, Pirttilä TA. Coeliac disease in patients with cerebellar ataxia of unknown origin. *Ann Med* 2001; 33: 445-449.
16. Hadjivassiliou M, Grunewald R, Sharrack B, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. *Brain* 2003; 126: 685-691.
17. Bernasconi A, Bernasconi N, Andermann F, et al. Celiac disease, bilateral occipital calcifications and intractable epilepsy: mechanisms of seizure origin. *Epilepsia* 1998; 39: 300-306.
18. Cronin CC, Jackson LM, Feighery C, et al. Coeliac disease and epilepsy. *QJM* 1998; 91: 303-308.
19. Spina M, Incorpora G, Trigilia T, Branciforte F, Franco G, Di Gregorio F. Headache as atypical presentation of celiac disease: report of a clinical case. *Pediatr Med Chir* 2001; 23: 133-135.
20. Hadjivassiliou M, Chattopadhyay AK, Grunewald RA, et al. Myopathy associated with gluten sensitivity. *Muscle Nerve* 2007; 35: 443-450.
21. Luostarinen L, Himanen SL, Luostarinen M, Collin P, Pirttilä T. Neuromuscular and sensory disturbances in patients with well treated coeliac disease. *J Neurol Neurosurg Psychiatry* 2003; 74: 490-494.
22. Taddeucci G, Bonuccelli A, Polacco P. Diagnosis of coeliac disease in patients with isolated neuropsychological symptoms. *Pediatr Med Chir* 2005; 27: 43-45.
23. Green PH, Alaedini A, Sander HW, Brannagan TH 3rd, Latov N, Chin RL. Mechanisms underlying celiac disease and its neurologic manifestations. *Cell Mol Life Sci* 2005; 62: 791-799.
24. Hadjivassiliou M, Boscolo S, Davies-Jones GA, et al. The humoral response in the pathogenesis of gluten ataxia. *Neurology* 2002; 58: 1221-1226.
25. Wiendl H, Mehling M, Dichgans J, et al. The humoral response in the pathogenesis of gluten ataxia. *Neurology* 2003; 60: 1397-1399.
26. Briani C, Zara G, Alaedini A, et al. Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. *J Neuroimmunol* 2008; 195: 171-175.
27. Alaedini A, Green PH, Sander HW, et al. Ganglioside reactive antibodies in the neuropathy associated with celiac disease. *J Neuroimmunol* 2002; 127: 145-148.
28. Volta U, De Giorgio R, Granito A, et al. Anti-ganglioside antibodies in coeliac disease with neurological disorders. *Dig Liver Dis* 2006; 38: 183-187.
29. Briani C, Ruggero S, Zara G, et al. Anti-ganglioside antibodies in children with celiac disease: correlation with gluten-free diet and neurological complications. *Aliment Pharmacol Ther* 2004; 20: 231-235.
30. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. *J Bone Miner Res* 1999; 14: 652-657.
31. Mather KJ, Meddings JB, Beck PL, Scott RB, Hanley DA. Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. *Am J Gastroenterol* 2001; 96: 120-125.
32. Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. *Clin Gastroenterol Hepatol* 2003; 1: 19-22.
33. Sugai E, Cherniavsky A, Pedreira S, et al. Bone-specific antibodies in sera from patients with celiac disease: characterization and implications in osteoporosis. *J Clin Immunol* 2002; 22: 353-362.
34. Fornari MC, Pedreira S, Niveloni S, et al. Pre- and post-treatment serum levels of cytokines IL-1 beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? *Am J Gastroenterol* 1998; 93: 412-418.
35. Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. *Eur J Gastroenterol Hepatol* 2003; 15: 851-856.
36. Staun M, Jarnum S. Measurement of the 10,000-molecular weight calcium-binding protein in small intestinal biopsy specimens from patients with malabsorption syndromes. *Scand J Gastroenterol* 1988; 23: 827-832.

37. Caraceni MP, Molteni N, Bardella MT, Ortolani S, Nogara A, Bianchi PA. Bone and mineral metabolism in adult celiac disease. *Am J Gastroenterol* 1988; 83: 274-277.
38. Jameson S. Coeliac disease, insulin-like growth factor, bone mineral density, and zinc. *Scand J Gastroenterol* 2000; 35: 894-896.
39. Devine A, Rosen C, Mohan S, Baylink D, Prince RL. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor-binding proteins in post-menopausal women. *Am J Clin Nutr* 1998; 68: 200-206.
40. Wood RJ, Zheng JJ. High dietary calcium intakes reduce zinc absorption and balance in humans. *Am J Clin Nutr* 1997; 65: 1803-1809.
41. Valdimarsson T, Arnqvist HJ, Toss G, Järnerot G, Nyström F, Ström M. Low circulating insulin-like growth factor I in coeliac disease and its relation to bone mineral density. *Scand J Gastroenterol* 1999; 34: 904-908.
42. Farthing MJ, Rees LH, Dawson AM. Male gonadal function in coeliac disease: III. Pituitary regulation. *Clin Endocrinol* 1983; 19: 661-671.
43. Sher KS, Jayanthi V, Probert CS, Stewart CR, Mayberry JF. Infertility, obstetric and gynaecological problems in coeliac disease. *Dig Dis* 1994; 12: 186-190.
44. Meyer D, Stavropoulos S, Diamond B, Shane E, Green PH. Osteoporosis in a North American adult population with celiac disease. *Am J Gastroenterol* 2001; 96: 112-119.
45. Selimoğlu MA, Ertekin V, Altinkaynak S. Hyper-CK-emia in pediatric celiac disease: prevalence and clinical importance. *J Clin Gastroenterol* 2007; 41: 667-670.
46. Lepore L, Martellosi S, Pennesi M, et al. Prevalence of celiac disease in patients with juvenile chronic arthritis. *J Pediatr* 1996; 129: 311-313.
47. Pollock DJ. The liver in coeliac disease. *Histopathology* 1977; 1: 421-430.
48. Farre C, Esteve M, Curcoy A, et al. Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. *Am J Gastroenterol* 2002; 97: 3176-3181.
49. Selimoğlu MA, Alp H, Ertekin V. Is rhabdomyolysis a rare manifestation in celiac disease? *Yonsei Med J* 2004; 45: 759-760.
50. Sorensen HT, Thulstrup AM, Blomqvist P, Nørgaard B, Fonager K, Ekbohm A. Risk of primary biliary liver cirrhosis in patients with celiac disease: Danish and Swedish cohort study. *Gut* 1999; 44: 736-738.
51. Lawson A, West J, Aithal GP, Logan RF. Autoimmune cholestatic liver disease in people with celiac disease: a population-based study of their association. *Aliment Pharmacol Ther* 2005; 21: 401-405.
52. Freeman HJ. Hepatobiliary and pancreatic disorders in celiac disease. *World J Gastroenterol* 2006; 12: 1503-1508.
53. Morris WE Jr. Hemochromatosis and celiac sprue. Case report. *J Fla Med Assoc* 1993; 80: 243-245.
54. Heneghan MA, Feeley KM, Stevens FM, Little MP, McCarthy CF. Precipitation of iron overload and hereditary hemochromatosis after successful treatment of celiac disease. *Am J Gastroenterol* 2000; 95: 298-300.
55. Turcu A, Lévêque L, Bielefeld P, Besancenot JF, Hillon P. Adult celiac disease and hemochromatosis. *Am J Gastroenterol* 2000; 95: 3661-3662.
56. Butterworth JR, Cooper BT, Rosenberg WM, et al. The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. *Gastroenterology* 2002; 123: 444-449.
57. Bowlus CL, Lie BA. Discussion of the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease. *Gastroenterology* 2003; 124: 1562-1563.
58. Humbert P, Pelletier F, Dreno B, Puzenat E, Aubin F. Gluten intolerance and skin diseases. *Eur J Dermatol* 2006; 16: 4-11.
59. Tasanen K, Raudasoja R, Kallioinen M, Ranki A. Erythema elevatum diutinum in association with coeliac disease. *Br J Dermatol* 1997; 136: 624-627.
60. Loche F, Bazex J. Celiac disease associated with cutaneous sarcoidosis granuloma. *Rev Med Interne* 1997; 18: 975-978.
61. Egan CA, Smith EP, Taylor TB, Meyer LJ, Samowitz WS, Zone JJ. Linear IgA bullous dermatosis responsive to a gluten-free diet. *Am J Gastroenterol* 2001; 96: 1927-1929.
62. Seyhan M, Erdem T, Ertekin V, Selimoğlu MA. The mucocutaneous manifestations associated with celiac disease in childhood and adolescence. *Pediatr Dermatol* 2007; 24: 28-33.
63. Seyhan M. Çölyak hastalığında deri bulguları. In: Selimoğlu MA (ed). *Çölyak Hastalığı* (1st ed.) İstanbul: Logos Medical Press; 2008: 107-120.
64. Gasbarrini G, Malandrino N, Giorgio V, et al. Celiac disease: what's new about it? *Dig Dis* 2008; 26: 121-127.
65. Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. *Blood* 2007; 109: 412-421.
66. Brousse N, Meijer JW. Malignant complications of coeliac disease. *Best Pract Res Clin Gastroenterol* 2005; 19: 401-412.
67. Puri AS, Garg S, Monga R, Tyagi P, Saraswat MK. Spectrum of atypical celiac disease in North Indian children. *Indian Pediatr* 2004; 41: 822-827.
68. Ackerman Z, Eliakim R, Stalnikowicz R, Rachmilewitz D. Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. *Am J Gastroenterol* 1996; 91: 2099-2102.
69. Grisolano SW, Oxentenko AS, Murray JA, Burgart LJ, Dierkhising RA, Alexander JA. The usefulness of routine small bowel biopsies in evaluation of iron deficiency anemia. *J Clin Gastroenterol* 2004; 38: 756-760.

70. de Vizia B, Poggi V, Conenna R, Fiorillo A, Scippa L. Iron absorption and iron deficiency in infants and children with gastrointestinal diseases. *J Pediatr Gastroenterol Nutr* 1992; 14: 21-26.
71. Kosnai I, Kuitunen P, Siimes MA. Iron deficiency in children with coeliac disease on treatment with gluten-free diet: role of intestinal blood loss. *Arch Dis Child* 1979; 54: 375-378.
72. Shamir R, Levine A, Yalon-Hacohen M, et al. Faecal occult blood in children with coeliac disease. *Eur J Pediatr* 2000; 159: 832-834.
73. Logan RF, Howarth GF, West J, Shepherd K, Robinson MH, Hardcastle JD. How often is a positive faecal occult blood test the result of coeliac disease? *Eur J Gastroenterol Hepatol* 2003; 15: 1097-1100.
74. Mant MJ, Bain VG, Maguire CG, Murland K, Yacyshyn BR. Prevalence of occult gastrointestinal bleeding in celiac disease. *Clin Gastroenterol Hepatol* 2006; 4: 451-454.
75. Duggan JM. Coeliac disease: the great imitator. *Med J Aust* 2004; 180: 524-526.
76. Goyens P, Brasseur D, Cadranel S. Copper deficiency in infants with active celiac disease. *J Pediatr Gastroenterol Nutr* 1985; 4: 677-680.
77. Fisgin T, Yarali N, Duru F, Usta B, Kara A. Hematologic manifestation of childhood celiac disease. *Acta Haematol* 2004; 111: 211-214.
78. Saibeni S, Lecchi A, Meucci G, et al. Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. *Clin Gastroenterol Hepatol* 2005; 3: 574-580.
79. Cavallaro R, Iovino P, Castiglione F, et al. Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. *Eur J Gastroenterol Hepatol* 2004; 16: 219-223.
80. Ertekin V, Selimoglu MA. Prevalence of prolonged prothrombin time in children with coeliac disease. *Eur J Gastroenterol Hepatol* 2006; 18: 579-580.
81. Green PH, Jabri B. Coeliac disease. *Lancet* 2003; 362: 383-391.
82. Ansaldi N, Palmas T, Corrias A, et al. Autoimmune thyroid disease and celiac disease in children. *J Pediatr Gastroenterol Nutr* 2003; 37: 63-66.
83. Ertekin V, Selimoglu MA, Doneray H, Orbak Z, Ozkan B. Prevalence of celiac disease in a sample of Turkish children and adolescents with type 1 diabetes mellitus. *J Clin Gastroenterol* 2006; 40: 655-657.
84. Selimoğlu MA, Ertekin V. Autoimmune thyroid disease in children with celiac disease. *J Pediatr Gastroenterol Nutr* 2005; 40: 611.
85. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. *Am J Med* 2003; 115: 191-195.
86. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease-effect of a gluten free diet. *Gut* 1989; 30: 333-338.
87. Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. *JAMA* 2002; 287: 1413-1419.
88. Ozgör B, Selimoglu MA. Coeliac disease and reproductive disorders. *Scand J Gastroenterol* 2010; 45: 395-402.
89. Bona G, Marinello D, Oderda G. Mechanisms of abnormal puberty in coeliac disease. *Horm Res* 2002; 57: 63-65.
90. Abaci A, Esen I, Unuvar T, Arslan N, Bober E. Two cases presenting with pubertal delay and diagnosed as celiac disease. *Clin Pediatr (Phila)* 2008; 47: 607-609.
91. Ciacci C, De Rosa A, de Michele G, et al. Sexual behaviour in untreated and treated coeliac patients. *Eur J Gastroenterol Hepatol* 1998; 10: 649-651.
92. Martinelli P, Troncone R, Paparo F, et al. Coeliac disease and unfavourable outcome of pregnancy. *Gut* 2000; 46: 332-335.
93. Sher KS, Mayberry JF. Female fertility, obstetric and gynaecological history in coeliac disease: a case control study. *Acta Paediatr Suppl* 1996; 412: 76-77.
94. Ciacci C, Cirillo M, Auriemma G, Di Dato G, Sabbatini F, Mazzacca G. Celiac disease and pregnancy outcome. *Am J Gastroenterol* 1996; 91: 718-722.
95. Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K, Mustonen J. Celiac disease and HLA DQ in patients with IgA nephropathy. *Am J Gastroenterol* 2002; 97: 2572-2576.
96. Fornasieri A, Sinico RA, Maldifassi P, Bernasconi P, Vegni M, D'Amico G. IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease). *Br Med J* 1987; 295: 78-80.
97. Ludvigsson JF, Montgomery SM, Olén O, Ekblom A, Ludvigsson J, Fored M. Coeliac disease and risk of renal disease—a general population cohort study. *Nephrol Dial Transplant* 2006; 21: 1809-1815.
98. Holmes GK. Non-malignant complications of coeliac disease. *Acta Paediatr Suppl* 1996; 412: 68-75.
99. Addolorato G, Mirijello A, D'Angelo C, et al. Social phobia in coeliac disease. *Scand J Gastroenterol* 2008; 43: 410-415.
100. Hallert C, Astrom J, Sedvall G. Psychological disturbances in adult coeliac disease. III. Reduced central monoamine metabolism and sign of depression. *Scand J Gastroenterol* 1982; 17: 21-24.
101. Ertekin V, Selimoglu MA, Gursan N, Ozkan B. Idiopathic pulmonary hemosiderosis in children with celiac disease. *Respir Med* 2006; 100: 568-569.